12:00 AM
 | 
Mar 11, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

AV0113 regulatory update

EMA granted Orphan Drug designation for Activartis' AV0113 to treat glioma. The...

Read the full 37 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >